Besides therapeutic purposes, it is helpful to perform BRAF mutational testing to differentiate between hereditary (e.g., Lynch Syndrome) and somatic CRC, especially when the neoplasia shows MSI with loss of MLH-1 expression shown by IHC and there is no ability to test MLH-1 methylation to confirm somatic origin. This evidence concerns the gene MLH1 and Lynch syndrome.